1. Moskowitz, AJ, Perales, MA, Kewalramani, T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158–163.
Google Scholar | Crossref | Medline2. Piñana, JL, Sanz, J, Esquirol, A, et al. Umbilical cord blood transplantation in adults with advanced Hodgkin’s disease: high incidence of post-transplant lymphoproliferative disease. Eur J Haematol 2016; 96: 128–135.
Google Scholar | Crossref | Medline3. Sureda, A, Stavrik, SG, Boumendil, A, et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2020; 55: 2170–2179.
Google Scholar | Crossref | Medline4. Chen, R, Gopal, AK, Smith, SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562–1566.
Google Scholar | Crossref | Medline | ISI5. Armand, P, Engert, A, Younes, A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018; 36: 1428–1439.
Google Scholar | Crossref | Medline6. Chen, R, Zinzani, PL, Lee, HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019; 134: 1144–1153.
Google Scholar | Crossref | Medline7. Rossi, C, Gilhodes, J, Maerevoet, M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. Epub ahead of print 8 June 2018. DOI: 10-1002/ajh.25154.
Google Scholar | Crossref8. Lepik, KV, Mikhailova, NB, Kondakova, EV, et al. A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere 2020; 4: e401.
Google Scholar | Crossref | Medline9. Baues, C, Trommer-Nestler, M, Jablonska, K, et al. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy 2017; 9: 423–433.
Google Scholar | Crossref | Medline10. Herrera, AF, Chen, RW, Palmer, J, et al. PET-adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Blood 2019; 134(Supplement_1): 239.
Google Scholar | Crossref | Medline11. Nie, J, Wang, C, Liu, Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 2019; 37: 1479–1489.
Google Scholar | Crossref | Medline12. Herrera, AF, Chen, L, Popplewell, LL, et al. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood 2019; 134(Supplement_1): 759.
Google Scholar | Crossref13. Ramchandren, R, Domingo-Domènech, E, Rueda, A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II Checkmate 205 Study. J Clin Oncol 2019; 37: 1997–2007.
Google Scholar | Crossref | Medline14. Bröckelmann, PJ, Goergen, H, Keller, U, et al. Efficacy of nivolumab and AVD in early-stage unfavourable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol 2020; 6: 1–9.
Google Scholar | Crossref15. Allen, PB, Savas, H, Evens, AM, et al. Pembrolizumab followed by AVD in untreated early unfavourable stage classical Hodgkin lymphoma. Blood. Epub ahead of print 29 September 2020. DOI: 10.1182/blood.20200007400.
Google Scholar | Crossref16. Carreau, NA, Pail, O, Armand, P, et al. Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy. Oncologist 2020; 25: 878–885.
Google Scholar17. Galluzzi, L, Senovilla, L, Zitvogel, L, et al. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215–233.
Google Scholar | Crossref | Medline18. Galluzzi, L, Zitvogel, L, Kroemer, G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res 2016; 4: 895–902.
Google Scholar | Crossref | Medline | ISI19. Cubas, R, Moskalenko, M, Cheung, J, et al. Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses. J Immunol 2018; 201: 2273–2286.
Google Scholar | Crossref | Medline20. Herbaux, C, Gauthier, J, Brice, P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 2017; 129: 2471–2478.
Google Scholar | Crossref | Medline21. Martínez, C, Carpio, C, Heras, I, et al. Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapsed/refractory Hodgkin lymphoma: real-life experience in Spain. Biol Blood Marrow Transplant 2020; 26: 1534–1542.
Google Scholar | Crossref | Medline22. Merryman, RW, Castagna, L, Giordano, L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. Epub ahead of print 3 March 2021. DOI: 10.1038/s41375-021-01193-6.
Google Scholar | Crossref | Medline23. Ijaz, A, Khan, AY, Malik, SU, et al. Significant risk of graft-versus-host-disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019; 25: 94–99.
Google Scholar | Crossref | Medline24. Dada, R, Usman, B. Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety. Eur J Haematol 2019; 102: 150–156.
Google Scholar | Crossref | Medline25. Montoro, J, Piñana, JL, Hernández-Boluda, JC, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant 2020; 55: 2147–2159.
Google Scholar | Crossref | Medline